BBPWM
CNCR

Blue Bell Private Wealth Management’s ETF Series Solutions Trust Range Cancer Therapeutics ETF CNCR Stock Holding History

Blue Bell Private Wealth Management’s Portfolio CNCR Stock Details CNCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-723
Closed -$6.82K – 735
2025
Q1 		$6.82K Hold
723
– – ﹤0.01% 548
2024
Q4 		$8.9K Hold
723
– – ﹤0.01% 507
2024
Q3 		$10.8K Hold
723
– – ﹤0.01% 517
2024
Q2 		$9.76K Hold
723
– – ﹤0.01% 524
2024
Q1 		$12K Sell
723
-698
-49% -$10.7K ﹤0.01% 505
2023
Q4 		$19.1K Sell
1,421
-287
-17% -$3.14K ﹤0.01% 433
2023
Q3 		$18.7K Buy
1,708
+1
+0.1% +$12 0.01% 368
2023
Q2 		$22.1K Hold
1,707
– – 0.01% 346
2023
Q1 		$20.5K Hold
1,707
– – 0.01% 317
2022
Q4 		$23.4K Sell
1,707
-200
-10% -$2.93K 0.01% 294
2022
Q3 		$28K Hold
1,907
– – 0.01% 263
2022
Q2 		$29K Hold
1,907
– – 0.01% 265
2022
Q1 		$34K Hold
1,907
– – 0.01% 260
2021
Q4 		$45K Buy
1,907
+533
+39% +$14.8K 0.01% 218
2021
Q3 		$42K Sell
1,374
-500
-27% -$15.1K 0.01% 110
2021
Q2 		$60K Hold
1,874
– – 0.02% 107
2021
Q1 		$56K Buy
1,874
+440
+31% +$14.3K 0.02% 111
2020
Q4 		$50K Sell
1,434
-410
-22% -$12.3K 0.02% 102
2020
Q3 		$51K Hold
1,844
– – 0.02% 105
2020
Q2 		$50K Sell
1,844
-100
-5% -$2.46K 0.02% 100
2020
Q1 		$38K Hold
1,944
– – 0.02% 107
2019
Q4 		$46K Sell
1,944
-100
-5% -$2.12K 0.02% 113
2019
Q3 		$38K Hold
2,044
– – 0.02% 116
2019
Q2 		$43K Hold
2,044
– – 0.02% 111
2019
Q1 		$43K Sell
2,044
-16
-0.8% -$336 0.02% 113
2018
Q4 		$39K Hold
2,060
– – 0.02% 112
2018
Q3 		$51K Buy
2,060
+410
+25% +$10.1K 0.02% 118
2018
Q2 		$40K Buy
1,650
+250
+18% +$6.74K 0.02% 125
2018
Q1 		$40K Hold
1,400
– – 0.02% 133
2017
Q4 		$33K Buy
1,400
+390
+39% +$9.85K 0.01% 137
2017
Q3 		$27K Sell
1,010
-190
-16% -$4.62K 0.01% 143
2017
Q2 		$28K Buy
1,200
+400
+50% +$9.05K 0.01% 149
2017
Q1 		$19K Hold
800
– – 0.01% 161
2016
Q4 		$17K Hold
800
– – 0.01% 169
2016
Q3 		$21K Hold
800
– – 0.01% 286
2016
Q2 		$19K Buy
800
+400
+100% +$9.14K 0.01% 298
2016
Q1 		$9K Hold
400
– – 0.01% 363
2015
Q4 		$11K Buy
+400
New +$11.5K 0.01% 361

Other funds holding CNCR

Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Blue Bell Private Wealth Management's CNCR Position: Q2 2025 in Review

Blue Bell Private Wealth Management sold out of ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) in Q2 2025, closing a stake of 723 shares — an estimated $6.82K sold.

Blue Bell Private Wealth Management first reported a position in CNCR in Q4 2015 and held it in 38 quarters. The position peaked at $60K in Q2 2021. 1 fund tracked by Wall St. Rank holds CNCR as of Q2 2025.

  • Blue Bell Private Wealth Management reported no remaining ETF Series Solutions Trust Range Cancer Therapeutics ETF position as of Q2 2025 after selling out during the quarter.
  • Blue Bell Private Wealth Management sold 723 ETF Series Solutions Trust Range Cancer Therapeutics ETF shares in Q2 2025, an estimated $6.82K.
  • Blue Bell Private Wealth Management first reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF in Q4 2015 and held it in 38 quarters.
  • Blue Bell Private Wealth Management's ETF Series Solutions Trust Range Cancer Therapeutics ETF position peaked at $60K in Q2 2021.
  • 1 fund tracked by Wall St. Rank held ETF Series Solutions Trust Range Cancer Therapeutics ETF as of Q2 2025.

Based on Blue Bell Private Wealth Management's 13F filing for Q2 2025, filed 11 Aug 2025.